{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihvdzp3khdvokdyerpfdy4sruwg4s7tp2om4w62cfcqu6s253e57u",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnmsn6zwfbu2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieloetnnh46ftwza354lbgyun7brkc5nsmzc6e745krgkjf6itium"
    },
    "mimeType": "image/jpeg",
    "size": 63054
  },
  "path": "/2026/06/06/pfizer-obesity-drug-berobenatide-metsera-results/?utm_campaign=rss",
  "publishedAt": "2026-06-06T13:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "drug development",
    "Obesity",
    "Pfizer",
    "Pharmaceuticals",
    "STAT+",
    "weight loss"
  ],
  "textContent": "Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.",
  "title": "STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential",
  "updatedAt": "2026-06-06T12:33:04.000Z"
}